Hepatocellular Carcinoma also known as HCC is the most common form of liver cancer in Australia with an increasing incidence and disease burden. HCC usually occurs due to underlying chronic liver disease and/or cirrhosis. In those with risk factors for developing HCC the current guidelines recommend regular 6 monthly surveillance with liver ultrasound and blood tests.
Our dedicated team at Monash Gastroenterology endeavour to provide the highest quality treatment to patients with HCC through coordinated care from diagnosis, treatment and clinical follow-up.
Referred cases of suspected or confirmed HCC are first reviewed at a fortnightly multidisciplinary team (MDT) meeting. This group includes Radiologists, Gastroenterologists, Surgeons, Oncologists, Radiation Oncologists, Palliative care team, and HCC Clinical Nurse Specialists.
Following review of imaging scans and clinical information, the MDT then recommends the optimal management for each case based on current international guidelines (EASL & AASLD). The treatment options include liver transplantation, surgical resection, locoregional therapy such as microwave ablation (MWA) or transarterial chemoembolization (TACE), radiotherapy and supportive care. Enrollment in current clinical trials is also offered to patients that are within eligibility criteria.
External referrals to our HCC service can be submitted to the Monash Gastroenterology Department by your GP or specialist and internal referrals can be submitted electronically on SMR.
Further information regarding HCC can also be found on the following links